Cure8 research brief
This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and clinical data are scarce, so it’s not ready to replace standard treatments.
Researchers studying natural-product therapeutics, clinicians interested in adjunctive IBD therapies, and patients curious about complementary approaches to gut barrier support.
This review summarizes experimental and limited clinical evidence on Aloe vera polysaccharides (APs) in inflammatory bowel disease.
The authors report that APs may act on multiple components of the intestinal barrier—tight junctions, mucin secretion, epithelial repair—modify the gut microbiota (prebiotic effects), reduce oxidative stress, and modulate immune signaling pathways such as NF-κB and JAK/STAT.
Most supporting studies are preclinical (animal and in vitro), with only a few small clinical studies noted.
The paper highlights potential advantages (multi-target mechanisms, favorable safety profile in available studies) but stresses major gaps: lack of robust clinical trials, limited pharmacokinetic and structure–activity data, and need for long-term safety evaluation.
The review does not provide new clinical efficacy data; it synthesizes existing literature up to 2026 and calls for rigorous randomized trials. If you are considering Aloe vera products, this review does not establish clinical benefit or dosing guidance for IBD.
Talk with your care team before trying supplements, especially if you are on immunosuppressants or biologics, since interactions and quality/control of preparations vary.
The review is an ethnopharmacological synthesis based on studies through 2026, but most evidence comes from animal and laboratory models. The authors call for detailed pharmacokinetic studies, safety monitoring, standardized product characterization, and randomized clinical trials.
This article provides an evidence overview (abstract-level summary) rather than new trial results.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
